Pricing Log in Create free account
Friday 6 November 2026 Export ABT’s income statement to Excel — free account

Abbott Laboratories

ABT Healthcare Medical Devices

Abbott Laboratories' revenue for fiscal 2025 (year ended December 2025) was $44.3 billion, up 5.67% from fiscal 2024.

Revenue
+14.5%
EPS
−43.6%
Free cash flow
+28.9%
Total debt
+142.7%

Quarter to September 2026, against a year earlier

110.08 3.52 −3.10%
Market cap
$196.6B
P/E
42.3×
Fwd P/E
35.1×
Dividend yield
2.22%
F-score
5/9
Altman Z
5.61
Beneish M
−2.50
Dividend safety
62/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Abbott Laboratories 10-Q filed Oct 29, 2025

Fiscal Q3 2025 · Period ended Sep 30, 2025 · Filed · accepted 4:22 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Jul 30, 2025: 1 removed · 18 modified; 8 with only figures updated

  1. Modified · Financial Review — Results of Operations

    The 6.95.5 percent increase in total net sales during the secondthird quarter of 2025, excluding the impact of foreign exchange, primarily reflected higher product sales in the Medical Devices and Established Pharmaceutical Products segments. Diagnostic Products sales continued to be impacted by the decline in COVID-19 testing-related sales and challenging market conditions in China, including the impact of volume-based procurement programs in China. COVID-19 testing-related sales were $5569 million in the secondthird quarter of 2025 compared to $102265 million in the secondthird quarter of 2024. Abbott’s net sales were favorably impacted by changes in foreign exchange rates in the secondthird quarter as the relatively weaker U.S. dollar increased total international sales by 0.82.3 percent and total sales by 0.51.4 percent.